Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Buprenorphine for Neonatal Abstinence Syndrome
NCT02249026Phase 2Unknown
- Start
- Oct 2014
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of buprenorphine in neonatal abstinence syndrome (NAS). Primary endpoint: Assessment of vital signs. Status: unknown.
02
Drugs
buprenorphine
03
Conditions
neonatal abstinence syndrome (NAS)
Beyond the preview
Go deeper on NCT02249026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249026.